PharmaShots | Incisive News in 3 Shots

Subscribe Now

T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and with...

August 9, 2021

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

March 23, 2021

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

January 13, 2021

Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

January 13, 2021

Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

December 30, 2020

Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

November 10, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us